Market Overview

Preview: Myriad Genetics's Earnings


On Thursday, August 13, Myriad Genetics (NASDAQ: MYGN) will report its last quarter's earnings. Here is Benzinga's preview of the company's release.

Earnings and Revenue

Analysts are expecting Myriad Genetics to report a loss of $0.47 per share. Revenue will likely be around $93.85 million, according to the consensus estimate. In the same quarter last year, Myriad Genetics reported EPS of $0.41 on revenue of $215.40 million. The Wall Street estimate would represent a 214.63% decline in the company's earnings. In comparison to analyst estimates in the past, here's how the company's reported EPS stacks up:

Quarter Q3 2020 Q2 2020 Q1 2019 Q4 2019
EPS Estimate 0.02 0.31 0.32 0.47
EPS Actual -0.08 0.23 0.08 0.41
Revenue Estimate 167.19 M 209.81 M 202.10 M 221.04 M
Revenue Actual 164.00 M 195.10 M 186.30 M 215.40 M

Stock Performance

Over the past 52-week period, shares of Myriad Genetics have declined 46.34%.

Bearing these returns in mind, shareholders will probably be dissatisfied going into this earnings release.

Don't be surprised to see the stock move on comments made during its conference call. Myriad Genetics is scheduled to hold the call at 16:30:00 ET and can be accessed here:


Related Articles (MYGN)

View Comments and Join the Discussion!

Posted-In: Earnings